Technical Analysis for MYGN - Myriad Genetics, Inc.

Grade Last Price % Change Price Change
B 27.84 -2.08% -0.59
MYGN closed down 2.08 percent on Friday, March 5, 2021, on 70 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down
Historical MYGN trend table...

Date Alert Name Type % Chg
New Downtrend Bearish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
BB Squeeze + Lower Band Touch Range Contraction 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Bollinger Band Squeeze Range Contraction -2.08%
Bollinger Band Squeeze Range Contraction -3.20%
BB Squeeze + Lower Band Touch Range Contraction -3.20%
Lower Bollinger Band Touch Weakness -3.20%
Fell Below 20 DMA Bearish -2.76%
Bollinger Band Squeeze Range Contraction -2.76%
Older End-of-Day Signals for MYGN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Myriad Genetics, Inc. Description

Myriad Genetics, Inc., a molecular diagnostic company, focuses on the development and marketing of predictive medicine, personalized medicine, and prognostic medicine tests primarily in the United States. The company's molecular diagnostic tests are designed to analyze genes, their mutations, expression levels, and proteins to assess an individual's risk for developing disease later in life; determine a patient's likelihood of responding to a particular drug; and assess a patient's risk of disease progression and disease recurrence. It offers various molecular diagnostic tests that include BRACAnalysis and BART, which are predictive medicine tests for hereditary breast and ovarian cancer; COLARIS predictive medicine test for hereditary colorectal and uterine cancer; COLARIS AP predictive medicine test for hereditary colorectal cancer; MELARIS predictive medicine test for hereditary melanoma; PANEXIA, a predictive medicine test for pancreatic cancer; PREZEON, a personalized and prognostic medicine test for cancer; Prolaris, a prognostic medicine test for prostate cancer; and TheraGuide 5-FU, a personalized medicine test for drug toxicity. The company, through its subsidiary, Myriad RBM, Inc., also offers biomarker discovery and companion diagnostic services to the pharmaceutical, biotechnology, and medical research industries that include multi-analyte profile testing services; multiplexed immunoassay kits; and TruCulture, a self-contained whole blood culture that allows pharmaceutical and biotechnology companies to identify drug toxicity prior to human trials. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.


Classification

Sector: Healthcare
Industry: Diagnostics & Research
Keywords: Medicine Biotechnology Cancer Clinical Medicine Disease Genetics Prostate Cancer Ovarian Cancer Multiplex Melanoma Lab Testing Medical Genetics Biomarker Diagnostic Tests Pancreatic Cancer Colorectal Cancer Medical Research Immunoassay Biomarkers Companion Diagnostic Diagnostic Services Personalized Medicine Whole Blood Breast And Ovarian Cancer Chemical Pathology Uterine Cancer

Is MYGN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 31.6
52 Week Low 9.24
Average Volume 801,678
200-Day Moving Average 17.15
50-Day Moving Average 26.46
20-Day Moving Average 29.61
10-Day Moving Average 29.43
Average True Range 1.75
ADX 35.43
+DI 18.26
-DI 22.45
Chandelier Exit (Long, 3 ATRs ) 26.35
Chandelier Exit (Short, 3 ATRs ) 32.01
Upper Bollinger Band 31.49
Lower Bollinger Band 27.73
Percent B (%b) 0.03
BandWidth 12.69
MACD Line 0.56
MACD Signal Line 1.06
MACD Histogram -0.4988
Fundamentals Value
Market Cap 2.09 Billion
Num Shares 75.2 Million
EPS 0.06
Price-to-Earnings (P/E) Ratio 464.00
Price-to-Sales 2.33
Price-to-Book 1.54
PEG Ratio 1.40
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 30.65
Resistance 3 (R3) 30.60 29.61 30.18
Resistance 2 (R2) 29.61 28.90 29.64 30.02
Resistance 1 (R1) 28.73 28.46 28.24 28.78 29.87
Pivot Point 27.74 27.74 27.50 27.77 27.74
Support 1 (S1) 26.86 27.03 26.37 26.91 25.81
Support 2 (S2) 25.87 26.59 25.90 25.66
Support 3 (S3) 24.99 25.87 25.50
Support 4 (S4) 25.04